title: Intraperitoneal chemotherapy for advanced ovarian and peritoneal cancers in patients following interval debulking surgery or primary cytoreductive surgery: Tom Baker Cancer Centre experience from 2006 to 2009.
abstract: OBJECTIVE
  To describe our experience with cisplatin- and paclitaxel-based IP chemotherapy in patients treated initially with either neoadjuvant chemotherapy and interval debulking surgery (IDS) or primary cytoreductive surgery (PCRS).
  
  
  METHODS
  We performed a retrospective review of the records of 67 patients (38 IDS, 29 PCRS) enrolled in the intraperitoneal (IP) chemotherapy program at the Tom Baker Cancer Centre between 2006 and 2009. Information pertaining to patient demographics, IP chemotherapy toxicity, and catheter complications was extracted, and the median time to recurrence was calculated.
  
  
  RESULTS
  Most patients in the study were aged 50 to 70 years and had a diagnosis of stage III serous ovarian cancer. Overall, 295/393 IP cycles (75%) were successfully administered. The proportion of patients completing six cycles of chemotherapy in the IDS and PCRS groups was 53% and 59%, respectively. Frequent (> 25%) Grade 1 to 2 chemotherapy toxicities included fatigue, peripheral neuropathy, and nausea. Catheter complications were observed in 34% of patients (23/67). The recurrence rates for patients completing four or more cycles of IP chemotherapy in the IDS and PCRS groups were 58% and 35%, respectively, with the median time to recurrence approximately one year.
  
  
  CONCLUSIONS
  Although IP chemotherapy is well tolerated in both IDS and PCRS patients, the median time to recurrence is shorter than expected.
authors.affiliation: Division of Gynecologic Oncology, Tom Baker Cancer Centre, Calgary AB.
authors.forename: Gregory
authors.initials: G
authors.lastname: Nelson
authors.forename: Carlos Aspe
authors.initials: CA
authors.lastname: Lucero
authors.forename: Pamela
authors.initials: P
authors.lastname: Chu
authors.forename: Jill
authors.initials: J
authors.lastname: Nation
authors.forename: Prafull
authors.initials: P
authors.lastname: Ghatage
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel; D002945:Cisplatin